AstraZeneca Annual Report and Principal Subsidiaries 112 Form 20-F Information 2003 Principal Subsidiaries Percentage of voting At 31 December 2003 Country share capital held Principal activity UK AstraZeneca UK Limited England 100# Research and development, production, marketing AstraZeneca Insurance Company Limited England 100 Insurance and reinsurance underwriting AstraZeneca Treasury Limited England 100 Treasury Continental Europe NV AstraZeneca SA Belgium 100 Marketing AstraZeneca Dunkerque Production SCS France 100 Production AstraZeneca SA France 100 Research, production, marketing AstraZeneca GmbH Germany 100 Development, production, marketing AstraZeneca Holding GmbH Germany 100 Production, marketing AstraZeneca SpA Italy 100 Production, marketing AstraZeneca Farmaceutica Spain SA Spain 100 Production, marketing AstraZeneca AB Sweden 100 Research and development, production, marketing AstraZeneca BV The Netherlands 100 Marketing The Americas AstraZeneca Canada Inc. Canada 100 Research, production, marketing IPR Pharmaceuticals Inc. Puerto Rico 100 Development, production, marketing AstraZeneca LP US 99 Research and development, production, marketing AstraZeneca Pharmaceuticals LP US 100 Research and development, production, marketing Zeneca Holdings Inc.
US 100 Production, marketing Asia, Africa & Australasia AstraZeneca Pty Limited Australia 100 Development, production, marketing AstraZeneca KK Japan 80 Production, marketing # Shares held directly The companies and other entities listed above are those whose results or financial position principally affected the figures shown in the Groups annual Financial Statements.
A full list of subsidiaries, joint ventures and associates will be annexed to the Companys next annual return filed with the Registrar of Companies.
The country of registration or incorporation is stated alongside each company.
The accounting dates of subsidiaries and associates are 31 December, except for Salick Health Care, Inc. which, owing to local conditions and to avoid undue delay in the preparation of the Financial Statements, is 30 November.
AstraZeneca operates through 234 subsidiaries worldwide.
The Group Financial Statements consolidate the Financial Statements of AstraZeneca PLC and its subsidiaries at 31 December 2003.
Products are manufactured in some 20 countries worldwide and are sold in over 100 countries.
